18-Fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract

Gastroenterology

Volumn 125, Issue 4, 2003, Pages 1235-1245

  Annovazzi, Allessio ^a   Peeters, Marc ^b   Maenhout, Annelies ^b   Signore, Alberto ^a   Dierckx, Rudi ^b   Van de Wiele, Christophe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BILE DUCT CARCINOMA; BILIARY TRACT TUMOR; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ESOPHAGUS CANCER; GASTROINTESTINAL TRACT NONENDOCRINE NEOPLASTIC DISORDER; GASTROINTESTINAL TUMOR; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; OCCULT CANCER; PANCREAS CANCER; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

EID: 0141594594     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)01208-3     Document Type: Article

References (118)

1. Jones T. The imaging science of positron emission tomography. Eur J Nucl Med 1996;23:807-813.
2. Som P, Atkins HL, Bandoypadhyay D, Fowler JJ, MacGregor RR, Matsin K, Oster ZH, Sacker DF, Shive CY, Turner H, Wan CN, Wolf AP, Zabinski SV. A fluorinated glucose analogue, 2-fluoro-2-deoxy-D-glucose (F-18): non-toxic tracer for rapid tumour detection. J Nucl Med 1980;21:670-675.
3. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
4. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-1495.
5. Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Stralenther Onkol 1999;175:356-373.
6. Dahlbom M, Hoffman E, Hoh CK, Schiepers C, Rosenqvist G, Hawkins RA, Phelps ME. Whole-body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med 1992;33:1191-1199.
7. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-1415.
8. Leiper K, Morris AI. Treatment of oesophago-gastric tumours. Endoscopy 2002;34:139-145.
9. Peters JH, Hoeft SF, Heimbucher J, Bremner RM, DeMeester TR, Bremner CG, Clark GW, Kiyabu M, Parisky Y. Selection of patients for curative or palliative resection of esophageal cancer based on preoperative endoscopic ultrasonography. Arch Surg 1994;129:534-539.
10. Chandawarkar RY, Kakegawa R, Fujita H, Yamana H, Hayabuthi N. Comparative analysis of imaging modalities in the preoperative assessment of nodal metastasis in esophageal cancer. J Surg Oncol 1996;61:214-217.
11. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Thoracoscopic staging and surgical therapy for esophageal cancer. Chest 1995;107:218-213.
12. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA, Cooper JD. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770-776.
13. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521-527.
14. Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 2001;71:290-294,
15. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921-928.
16. McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D, Park K, Nicolson M, Gilbert FJ, Sharp P. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999;72:525-529.
17. Vilgrain V, Mompoint D, Palazzo L, Menu Y, Gayet B, Ollier P, Nahum H, Fekete F. Staging of esophageal carcinoma: comparison of results with endoscopic sonography and CT. AJR Am J Roentgenol 1990;155:277-281.
18. Goei R, Lamers RJ, Engelshove HA, Oei KT. Computed tomographic staging of esophageal carcinoma: a study on interobserver variation and correlation with pathological findings. Eur J Radiol 1992;15:40-44.
19. Tio TL, Coene PP, Schouwink MH, Tytgat GN. Esophagogastric carcinoma: preoperative TNM classification with endosonography. Radiology 1989;173:411-417.
20. Massari M, Cioffi U, De Simone M, Lattuada E, Montorsi M, Segalin A, Bonavina L. Endoscopic ultrasonography for preoperative staging of esophageal carcinoma. Surg Laparosc Endosc 1997;7:162-165.
21. Korst RJ, Rusch VW, Venkatraman E, Bains MS, Burt ME, Downey RJ, Ginsberg RJ. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998;115:660-669.
22. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:417-424.
23. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA, Cooper JD. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770-776.
24. Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, Kim BT. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808-815.
25. Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, Urso GK, Dachille MA, Townsend DW. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer, comparison with computed tomography. Clin Nucl Med 2000;11:882-887.
26. Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, Meltzer CC. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133-1136.
27. Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, De Wever W, Coosemans W, Decker G, Deleyne P, Deneffe G, van Raemdonck D, Mortelmans L. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction. Ann Surg 2000;232:743-752.
28. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368.
29. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer (abstr). Am J Surg 2002;184:279.
30. Davis GR. Neoplasms of the stomach. In: Schleisinger MH, Fordtran J, ed. Gastrointestinal disease. (5th ed). Philadelphia: Saunders, 1994:763-848.
31. Elder JB. Carcinoma of the stomach. In: Haubrich WS, Schaffnerr F, ed. Bockus gastroenterology. (5th ed). Philadelphia: Saunders, 1995:854-874.
32. Tunaci M. Carcinoma of stomach and duodenum: radiologic diagnosis and staging. Eur J Radiol 2002;42:181-192.
33. Glimelius N, Ekström K, Hoffman K, Graf W, Sjodon PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-168.
34. Akoh JA, McIntyre IMC. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293-299.
35. Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Cancer 2000;89:255-261.
36. Fukuya T, Honda H, Hayashi T, Kaneko K, Tateshi Y, Po T, Maehara Y, Tanaka M, Tsuneyushi M, Masuda K. Lymph node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 1995;197:705-711.
37. McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D, Park K, Nicolson M, Gilbert FJ, Sharp P. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999;72:525-529.
38. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicholson M, Park KG. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403-1406.
39. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, Maes A, Mortelmans L. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med 2002;29:525-529.
40. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997;26:34-38.
41. Haydon GH, Hayes PC. Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1996;8:850-855.
42. Zornig C, Broelsch CE. Impact of staging on the treatment of hepatocellular carcinoma. Endoscopy 1993;25:138-142.
43. Honda H, Onitsuka H, Murakami J, Kaneko K, Murayama S, Adachi E, Kanemarsu T, Sugimachi K, Masuda K. Characteristic findings of hepatocellular carcinoma: an evaluation with comparative study of US, CT and MRI. Gastrointest Radiol 1992;17:245-249.
44. Winter TC, Takayasu K, Muramatsu Y, Furukawa H, Wakao F, Koga H, Sakamoto M, Hiroshashi S, Freeny PC. Early advanced hepatocellular carcinoma: evaluation of CT and MR appearance with pathologic correlation. Radiology 1994;192:379-387.
45. Yu JS, Kim KW, Lee JT, Yoo HS. MR imaging during arterial portography for assessment of hepatocellular carcinoma. Comparison with CT during arterial portography. AJR Am J Roentgenol 1998;170:1501-1506.
46. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-515.
47. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319.
48. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797.
49. Verhoef C, Valkema R, de Man RA, Krenning EP, Yzermans JN. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver 2002;22:51-56.
50. Weber G, Morris HP. Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumours of different growth rates. Cancer Res 1963;23:987-994.
51. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S, Ochi H. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-1880.
52. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-1969.
53. Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, Nishimura Y, Jo S, Masunaga S, Kubo S. Monitoring liver tumor therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr 1990;14:370-374.
54. Harder J, Blum HE. Cholangiocarcinoma. Schweiz Rundsch Med Prax 2002;91:1352-1356.
55. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663-671.
56. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808-819.
57. Bismuth H, Nakache R, Diamand T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992;215:31-38.
58. Blumgart LH, Benjamin IS. Liver resection for bile duct cancer. Surg Clin North Am 1989;69:323-337.
59. Glasbrenner B, Ardan M, Boeck W, Preclik G, Moller P, Adler G. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999;31:712-717.
60. Mansfield JC, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. Gut 1997;40:671-677.
61. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, Tage-Jensen U, Dahlerup JF. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998;28:700-706.
62. Fristcher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schäfer H, Buchert R, Rogiers X, Clausen M. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 2001;22:1277-1285.
63. Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, Seese A, Huster D, Berr F. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029-1035.
64. Taylor B. Roussel lecture. Management of adenocarcinoma of the head of the pancreas: 10 questions for the 1990s. Can J Surg 1996;39:271-283.
65. Trede M, Schwall G, Saeger D. Survival after pancreaticoduodenectomy: 118 consecutive resections without operative mortality. Ann Surg 1990;211:447-458.
66. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-125.
67. Del Frate C, Zanardi R, Mortele K, Ros PR. Advances in imaging for pancreatic disease. Curr Gastroenterol Rep 2002;4:140-148.
68. Lammer J, Herlinger H, Zalaudek G, Hofler H. Pseudotumorous pancreatitis. Gastrointest Radiol 1995;10:59-67.
69. Bluemke DA, Fishman EK. CT and MR evaluation of pancreatic cancer. Surg Clin N Am 1998;7:103-124.
70. Brandt KR, Charboneau JW, Stephens DH, Welch TJ, Goellner JR. CT- and US-guided biopsy of the pancreas. Radiology 1993;187:99-104.
71. Zimny M, Schumpelick. Fluorodeoxyglucose positron emission tomography (FDG-PET) for the differential diagnosis of pancreatic lesions. Der Chirurg 2001;9:989-994.
72. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784-1791.
73. Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, Sontheimer J, Farthmann EH. Evaluation of positron emission tomography with 2- [18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194-199.
74. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, Hosotani R, Imamura M, Konishi J. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554.
75. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. 18-Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-737.
76. Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, Imdahl A. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med 2002;29:237-242.
77. Kalady MF, Clary BM, Gottfried M, Rohren EM, Coleman RE, Pappas TN, Tyler DS. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 2002;9:799-806.
78. Valinas R, Barrier A, Montravers F, Houry S, Talbot JN, Huguier M. 18F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic cancer. Gastroenterol Clin Biol 2002;26:888-892.
79. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Bull U. Results of positron emission tomography with fluorine-18 labelled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma. Radiologe 1996;36:435-440.
80. Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, Beger HG, Reske SN, Values and limitations of 18-F fluorodeoxyglucose positron emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000;20:109-116.
81. Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastasis from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250-255.
82. Jadvar H, Fischman AJ. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001;26:254-259.
83. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000;52:367-371.
84. Franke C, Klpador R, Meyerhoff K, Schauman M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999;19:2437-2242.
85. Maisey NR, Webb A, Flux GD, Padhani A, Cunningham DC, Ott RJ, Norman A. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000;83:287-293.
86. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
87. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg 1996;83:293-304.
88. Galandiuk S, Wieand HS, Mortel CG, Cha SS, Fitzgibbons RJ, Jr, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27-32.
89. Moss AA. Imaging of colorectal carcinoma. Radiology 1989;170:308-310.
90. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) tests for monitoring patients with resected colon cancer. JAMA 1993;270:943-947.
91. Balthazar EJ. CT of the gastrointestinal tract: principles and interpretation. AJR Am J Roentgenol 1991;156:23-32.
92. Freeny PC, Marks WM, Ryan JA, Bolen JW. Colorectal carcinoma evaluation with CT: preoperative staging and detection of post-operative recurrence. Radiology 1986;158:347-353.
93. Ito K, Kato T, Tadokoro M, Ishiguchi T, Oshima M, Ishigaki T, Sakuma S. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992;182:549-552.
94. Gupta NC, Falk PM, Frank AL, Thorson AM, Frick MP, Bowman B. Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebr Med J 1993;78:30-35.
95. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Calontowicz PJ, Carbone GM, Spaulding MB. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755-760.
96. Mukai M, Sadahiro S, Yasuda S, Ishida H, Tokunaga N, Tajima T, Makuuchi H. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000;7:85-87.
97. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, Gambhir SS. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41:1177-1189.
98. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, Marchal G, Filez L, Aerts R. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-522.
99. Strauss LG, Glorius JH, Schlag P, Lehner B, Kimmis B, Engenhart R, Marin-Grez M, Helus F, Oberdorfer F, Schmidlin P. Recurrence of colorectal tumours: PET evaluation. Radiology 1989;170:329-332.
100. Ito K, Kato T, Tadokoro M, Ishiguchi T, Oshima M, Ishiyaki T, Sakuma S. Recurrent rectal cancer and scar: differentiation with PET and MRI imaging. Radiology 1992;182:549-552.
101. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, Fleshman J, Read TE, Philpott GW, Kodner JJ. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-620.
102. Lonneux M, Reffad AM, Detry R, Kartheuser A, Gigot JF, Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med 2002;29:915-921.
103. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002;43:492-499.
104. Flamen P, Stroobants S, van Cutsem E, Dupont P, Bormans G, De Vadder N, Penninckx F, van Hoe L, Mortelmans L. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894-901.
105. Arulampalam THA, Costa DC, Loizidou M, Visvikis S, Ell TJ, Taylor I. Positron emission tomography and colorectal cancer. Br J Surg 2001;88:176-189.
106. Delbeke D, Vitoal JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr, Chapman WC, Pinson WC. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-1201.
107. Lai DT, Fulham M, Stephen MS, Chu KM, Solomon M, Thompson JF, Sheldon DM, Storey DW. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703-707.
108. Valk PE, Abella-Columna E, Haseman MK, Pounds TR, Tesar RD, Myers RW, Greiss HB, Hofer GA. Whole-body PET imaging with [18F]fluorodeoxyglucose in the management of recurrent colorectal cancer. Arch Surg 1999;134:503-511.
109. Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. Arch Surg 1996;131:322-329.
110. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeong H, Finn RD, Cohen A, Kemeny N, Blumgart LH, Larson SM. Utility of FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178:282-287.
111. Beets G, Penninckx F, Schiepers C, Filez L, Mortelmans L, Kerremans R, Aerts R, De Roo M. Clinical value of whole-body positron emission tomography with 18F-fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81:1666-1670.
112. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319-323.
113. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, Peeters M, Penninckx F, Filez I, Bleichrodt RP, Mortermans L. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography. Eur J Cancer 2001;37:862-869.
114. Maldonado A, Sancho F, Cerdan J, Lozano A, Mohedano N, Jimenez J, Moya F, Zomeno M. FDG-PET in the detection of recurrence in colorectal cancer based on rising CEA-level. Experience in 72 patients (abstr). Clin Pos Imag 2000;3:170.
115. Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg 1999;86:932-937.
116. Haberkorn U, Strauss LG, Dimitrakopoulo A, Seiffert E, Obendorfer F, Ziegler S, Reisser C, Doll J, Helus F, van Kaick G. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-1490.
117. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hikisch T, Pratt B, Husband J, Flower M, Ott R. Non-invasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumour response to fluorouracil. J Clin Oncol 1996;14:700-708.
118. Guillem JG, Puig-La Calle J, Akhurst T, Tickoo S, Roo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeong H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Col Rect 2000;43:18-24.